• CLEAR A, a 16-patient phase-1 study of thrombolysis in IVH
  • CLEAR B, a 34-patient, phase-1 study of thrombolysis in IVH
  • MISTIE-II, a phase-II trial of thrombolysis in ICH
  • MISTIE-ICES, endoscopic evacuation in ICH
  • CLEAR-III, a 500-patient global trial in IVH
  • MISTIE-III, a 500-patient global trial in ICH
  • SLEUTH, feasibility of an ultrasound catheter in ICH
  • CARES, an 88-patient observational study
  • Hemorrhagic Stroke (ICH, IVH)
  • Ischemic Stroke, TIA
  • Global Ischemia
  • Traumatic Brain Injury (TBI)
  • Encephalitis
  • Functional & Cognitive Outcomes
  • Epilepsy
  • Neurosurgery
  • Data Coordinating Center (DCC)
  • Clinical Data Management
  • Advanced Biostatistics
  • Adaptive Randomization
  • Electronic Data Capture (EDC)
  • Electronic Trial Master File (eTMF)
  • Clinical Trial Management System (CTMS)
  • Online Training & Certification
  • Clinical Coordinating Center (CCC)
  • Centralized CT Reading Center
  • Surgical Support Center
  • Investigator Selection & Qualification
  • Clinical Site Management
  • Safety & Pharmacovigilance
  • On-site and Remote QA Monitoring
  • Regulatory (IND, IDE, GCP)

Brain Injury Outcomes (BIOS) is a research coordinating center at Johns Hopkins University, Department of Neurology.

Under the direction of Daniel F. Hanley, MD, a renowned expert in ischemic and hemorrhagic stroke, and with the managerial expertise of Karen Lane, since 1999, BIOS has been awarded more than 40 research grants from the National Institutes of Health (NIH), the FDA Orphan Drugs Program, pharmaceutical & medical device companies and medical societies. With the team's unique expertise, BIOS leads an international consortium of hospitals and medical institutions developing potentially life-saving new medical therapies for stroke and brain injury. Notable BIOS successes are the MISTIE and CLEAR programs, which are developing what could become the first validated treatments for hemorrhagic stroke, a form of bleeding in the brain.